Publications & Patient Newsletter
UVA Publications
2025
- Clinical and Genomic Features of Androgen Indifferent Prostate Cancer
- Genomic, transcriptomic, and immunogenomic landscape of over 1300 sarcomas of diverse histology subtypes – PubMed
2024
- Cancers | Free Full-Text | Clinical and Genomic Features of Patients with Renal Cell Carcinoma and Advanced Chronic Kidney Disease: Analysis of a Multi-Institutional Database (mdpi.com)
- Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human Cancers (gavinpublishers.com)
- PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness – PubMed (nih.gov)
- Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States – PubMed (nih.gov)
- Comparing the rate of immunotherapy treatment change due to toxicity by sex – Chua – 2024 – Cancer Reports – Wiley Online Library
- Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy
- Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities | npj Precision Oncology
- Distinctive genomic features of human T-lymphotropic virus type 1-related adult T-cell leukemia-lymphoma in Western populations – PubMed
2023
- Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes – PubMed (nih.gov)
- Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid Leukemia – PubMed (nih.gov)
- In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms
- The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors
- Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations
2022
- Replicative Instability Drives Cancer Progression
- CDK6 is a therapeutic target in myelofibrosis
- Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways
2021
- Assessing acute myeloid leukemia susceptibility in rearrangement-driven patients by DNA breakage at topoisomerase II and CCCTC-binding factor/cohesin binding sites
- Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL
2020